Hepatic steatosis is recognized as hepatic presentation of the metabolic syndrome. Hyperinsulinaemia, which shifts fatty acid oxidation to de novo lipogenesis and lipid storage in the liver, appears to be a principal elicitor particularly in the early stages of disease development. The impact of PGE 2 , which has previously been shown to attenuate insulin signaling and hence might reduce insulin-dependent lipid accumulation, on insulin-induced steatosis of hepatocytes was studied. The PGE 2 -generating capacity was enhanced in various obese mouse models by the induction of cyclooxygenase 2 and microsomal prostaglandin E-synthases (mPGES1, mPGES2). PGE 2 attenuated the insulin-dependent induction of SREBP-1c and its target genes glucokinase and fatty acid synthase. Nevertheless, PGE 2 enhanced incorporation of glucose into hepatic triglycerides synergistically with insulin. This was most likely due to a combination of a PGE 2 -dependent repression of (1) the key lipolytic enzyme adipose triglyceride lipase, (2) carnitine-palmitoyltransferase 1, a key regulator of mitochondrial b-oxidation, and (3) microsomal transfer protein, as well as (4) apolipoprotein B, key components of the VLDL synthesis. Repression of PGC1a, a common upstream regulator of these genes, was identified as a possible cause. In support of this hypothesis, overexpression of PGC1a completely blunted the PGE 2 -dependent fat accumulation. PGE 2 enhanced lipid accumulation synergistically with insulin, despite attenuating insulin signaling and might thus contribute to the development of hepatic steatosis. Induction of enzymes involved in PGE 2 synthesis in in vivo models of obesity imply a potential role of prostanoids in the development of NAFLD and NASH.
INTRODUCTION
With the rising prevalence of overweight, obesity and ensuing metabolic syndrome or type 2 diabetes, non-alcoholic fatty liver disease has become one of the most common liver pathologies. [1] [2] [3] The spectrum ranges from reversible fat accumulation (steatosis), which may be complicated by inflammation in steatohepatitis, to liver fibrosis, cirrhosis and ultimately organ loss. Although the exact mechanisms that determine the course of the disease remain elusive, hyperinsulinaemia and peripheral insulin resistance resulting in elevated levels of circulating free fatty acids appear to be among the principal causes of the initial steatosis. 1 Steatosis and inflammation seem to influence each other mutually: steatosis rendering the liver more susceptible to proinflammatory cytokines and cytokines in turn impairing the regulation of lipid metabolism in hepatocytes. In addition to cytokines, small molecular mass mediators, including prostaglandins 4 are released from non-parenchymal liver cells and infiltrating inflammatory cells. PGE 2 biosynthesis is upregulated by the induction of cyclooxygenase 2 (COX2) and microsomal prostaglandin E synthases 1 and 2 (mPGES1, mPGES2). 5, 6 Prostaglandins may affect hepatocyte metabolism directly 7 or they can modulate the regulation of hepatocyte metabolism by hormones 8, 9 or cytokines. 10, 11 There are conflicting reports about the impact of prostaglandins on hepatic lipid metabolism. Although some studies indicate that prostaglandins might favor fat accumulation in hepatocytes and hence the development of hepatic steatosis, 12 others provide evidence that PGE 2 rather might suppress de novo lipogenesis 13 or that PGE 2 does not affect lipogenesis but attenuate triglyceride incorporation into VLDL. 14 So far, the impact of prostaglandin E 2 on the insulin-dependent changes in hepatic lipid metabolism was not studied. This is of importance because hyperinsulinaemia contributes to the pathogenesis of hepatic steatosis. 2, 3 As we have previously shown that PGE 2 can attenuate insulin signaling, 8 we addressed the question whether PGE 2 is capable of attenuating insulin-dependent changes in hepatic lipid metabolism.
In accordance with such a hypothesis, PGE 2 attenuated the insulin-dependent induction of liponeogenic enzymes in in vitro studies with primary hepatocytes. At variance with the expectations, however, PGE 2 enhanced the incorporation of glucose into lipids synergistically with insulin, most likely by a combination of inhibiting b-oxidation and reducing lipoprotein secretion. In support of the in vivo relevance of such a mechanism, expression of inducible PGE 2 -generating enzymes was increased in livers of various models for diet-induced obesity as well as of monogenic and polygenic obesity.
MATERIALS AND METHODS Materials
Materials were from the following sources: Narcoreen, Merial GmbH (Hallbergmoos, Germany); Percoll, D-[U- 14 C] glucose, GE Healthcare (Freiburg, Germany); PGE 2 , PD98059, Alexis (Grünberg, Germany); monoclonal anti-phospho-Akt (Ser473), anti-phospho-p44/42 MAPK (Thr202/Tyr204), antiFoxO1 antibodies, polyclonal anti-Akt, anti-p44/42 MAPK, anti-phospho-FoxO1 (Thr24)/FoxO3a (Thr32), anti-phospho-ACC (Ser79) and anti-ACC antibodies, Cell Signaling Technology (Frankfurt, Germany); anti PGC1a, Santa Cruz Biotechnology (Heidelberg, Germany); and SuperSignal West Pico Chemiluminescent Substrate, Pierce (Rockford, IL, USA). The plasmid for eukaryotic expression of PGC1a was kindly provided by Stephan Herzig (DKFZ, Heidelberg, Germany).
Animals and Treatments
C3H/HouJ (Jackson Laboratories, Bar Harbor, ME, USA) mice had free access to standard diet (ssniff, Soest, Germany) and tap water containing 30% fructose or plain tap water for 8 weeks. 15 C57BL/6J, ob/ob (B6.V-Lep ob /J) (Charles River, Sulzfeld, Germany) and NZO mice (NZO/HIBomDife: Dr R Kluge, German Institute of Human Nutrition, Nuthetal, Germany) were kept on standard diet containing or high-fat diet (Altromin, Lage, Germany), as described previously, 16, 17 8 or 22 weeks at a temperature of 22 1C with a 12-h light/dark cycle. Mice were killed and portions of liver were snapfrozen.
Male Wistar rats (200-300 g) (Charles River) were kept on a 12-hour light/dark cycle with free access to water and a standard 1326 rat diet (Altromin).
Treatment of the animals followed the German animal protection laws and all experiments were approved by the ethics committee of the State Agency of Environment, Health and Consumer Protection (State of Brandenburg, Germany) and the principles of laboratory animal care.
Hepatocyte Cultivation
Density-gradient purified hepatocytes prepared without the use of collagenase and cultured in M199 (1 Â 10 6 cells/35-mm plate) as described previously. 18, 19 Unless otherwise stated, hepatocytes were incubated for 330 min with ± 10 mM PGE 2 , stimulated with ± 10 nM insulin for the time indicated, washed with ice-cold PBS and snapfrozen. Hepatocytes were transfected immediately after plating with the plasmids indicated employing a modified calcium phosphate method described previously. 20 Measurement of 14 C-Glucose Incorporation into Triglycerides Hepatocytes were preincubated ± 10 mM PGE 2 for 330 min supplemented with 1 mCi/ml 14 C-glucose, containing either 10 mM or 25 mM glucose. Subsequently, hepatocytes were incubated ±10 nM insulin for 6 h, washed with ice-cold PBS and lysed in 150 ml methanol. After adding 300 ml chloroform and sonication for 10 min, 90 ml of 0.05% CaCl 2 were added. After vigorous mixing, phases were separated by centrifugation at 5000 g for 10 min at room temperature. The chloroform phase was collected and the aqueous phase was re-extracted twice with chloroform as above. The combined chloroform phases were dried under vacuum and redissolved in 120 ml chloroform. Radioactivity in an aliquot of the extract was quantified by b-counting. 
Staining of Lipid Droplets

Measurement of Acetoacetate Formation
After incubation, hepatocytes were immediately lysed in 50 mM Tris/HCl pH 7.5 containing 50 mM sucrose, 4 mM MgCl 2 , 40 mM KCl, 2 mM EDTA; 10 mM NaF with protease inhibitors and 1 mM sodium orthovanadate (buffer 1). Crude mitochondria, which were prepared by centrifugation of the homogenates at 500 g at 4 1C and the supernatant for 10 min at 5000 g at 4 1C, were resuspended in buffer 1 and incubated for 60 min at 37 1C in the same buffer containing additionally 100 mM palmitate, 1 mM ATP and 1 mM D,L-Carnitine. The reaction was stopped by adding 1/10th reaction volume 30% TCA. Acetoacetate was determined in the deproteinized supernatants colorimetrically. 21 Western Blot Analysis and Quantitative PCR Proteins and phosphoproteins were quantified by western blot with phosphospecific antibodies as previously described. 8, 22 RNA was isolated with the Eurx Gene Matrix Universal RNA Purification Kit (Roboklon, Berlin, Germany) and from liver samples using peqGOLD TriFas (peqlab, Erlangen, Germany) or TRIzolReagent (Invitrogen, Darmstadt, Germany). cDNA was synthesized from purified, DNase-treated RNA as described previously. 8, 22 Hot start real-time RT-PCR for the quantification of mRNAs was carried out in triplicates in a reaction mixture of 2 Â Maxima SYBR Green qPCR Master Mix (MBI Fermentas GmbH, St. Leon Rot, Germany), 250 nM forward and reverse oligonucleotides (Table 1, .
RESULTS
Increased Expression of PGE 2 -Generating Enzymes in Obesity Models
In inflamed tissues local levels of PGE 2 are increased as a consequence of LPS-and cytokine-dependent induction of COX2 and mPGES1. 5, 6 Although mPGES2 is expressed constitutively, its expression can be enhanced in the course of inflammation. 23 Therefore, the mRNA expression of COX2, mPGES1 and mPGES2 was analyzed in the liver of mouse models, in which obesity was induced either by diet ( Figure 1 , left panel), age (middle panel) or leptin deficiency (right panel). In all these models development of obesity is accompanied by severe hepatic steatosis. [15] [16] [17] The respective controls are lean and devoid of hepatic pathology. In C3H/HouJ-mice fed with standard diet and tap water containing 30% fructose (the pathological model), mRNA expression of mPGES1 was 17-fold induced and expression of COX2 and mPGES2 were moderately increased by factor 1.5 in comparison with control mice fed with plain tap water ( Figure 1 ). Similar results were obtained in old (22 week, pathological model) versus young (8 week, control) NZO mice, a polygene obesity model for (human) metabolic syndrome, 16 fed with standard diet. COX2 was induced about two-fold, mPGES1 six-fold in the older, steatotic animals. Similarly, both COX2 (four-fold) and mPGES1 (7-fold) were increased in response to leptin deficiency when comparing the ob/ob (B6.V-Lep ob /J) with the corresponding healthy control strain C57BL/6J at 8 weeks of age when both strains are fed with standard diet (Figure 1 ). Data from further models of genetically or diet-induced obesity models yielded similar results (Supplementary Table S1 , see Supplementary Information).
Attenuation of Insulin-Induced Induction of Transcription Factors and Enzymes Involved in De Novo Lipogenesis
Fatty acid synthesis in hepatocytes is increased by insulin and high glucose concentration. Incubation of primary cultures of rat hepatocytes with PGE 2 before a subsequent stimulation with insulin attenuated the insulin-dependent phosphoryla- tion of the Akt kinase, which correlates with Akt activation, by about 50% (Figure 2) , independently of the glucose concentration in the culture medium. As shown previously, 8 this was due to a sustained PGE 2 -dependent activation of ERK1/2 (see Supplementary Figure S1 ). Inhibition of ERK1/2 by chemical inhibitors abrogated the PGE 2 -dependent inhibition of the insulin-dependent Akt-phosphorylation (see Supplementary Figure S1 ). In addition to acutely regulating enzyme activities of key metabolic enzymes Akt kinase mediates the insulin-dependent induction of the transcription factor SREBP-1c and its targets. It was assumed that the insulin-dependent induction of SREBP-1c and its targets might be attenuated by prior incubation of hepatocytes with PGE 2 . As expected, insulin-dependent five-fold induction of SREBP-1c was reduced about 60% by PGE 2 ( Figure 2 ). PGE 2 also reduced the basal SREBP-1c expression by about 30%. Glucose slightly induced basal SREBP-1c mRNA. Insulin induced SREBP-1c about four-fold above the level reached by incubation with 25 mM glucose alone, resulting in mRNA levels that were about seven-fold higher than under control conditions with 10 mM glucose. The insulin-dependent induction in presence of 25 mM glucose was attenuated by PGE 2 to a similar extent as in hepatocytes cultured in a medium containing 10 mM glucose. Figure S2 ). FAS was induced about four-fold by insulin under low-glucose conditions (Figure 2 ). This induction was largely attenuated by prior incubation of hepatocytes with PGE 2 . In contrast to SREBP-1c, the basal expression of FAS was not affected by PGE 2 treatment. Raising glucose concentration to 25 mM also induced FAS. Stimulation with insulin further induced FAS, resulting in a 10-fold induction in comparison with the control at 10 mM glucose. The insulin-dependent induction of FAS at high glucose was inhibited by prior treatment of the hepatocytes with PGE 2 by about 50%.
Incorporation of
14 C-Glucose into Lipids in Hepatocytes FAS is a key enzyme in de novo lipacidogenesis. Therefore, it was assumed that the attenuation of the insulin-dependent induction of FAS would be reflected in an attenuation of the insulin-induced incorporation of 14 C-glucose into hepatic triglycerides. At variance with expectations PGE 2 increased glucose incorporation into triglycerides in the absence of insulin both at low (10 mM) and at high (25 mM) glucose concentrations (Figure 3a) . At 10 mM glucose, PGE 2 further enhanced the insulin-stimulated incorporation of glucose into triglycerides while it did not affect the insulin-stimulated incorporation at 25 mM glucose. In accordance with this finding, deposition of fat droplets was seen in Oil Red-Ostained hepatocytes both after treatment with insulin and PGE 2 (Figure 3b and c) . The stimulation of lipid accumulation by PGE 2 and insulin appeared to be additive.
An acute stimulation of lipacidogenesis by PGE 2 -dependent covalent modification of the key regulatory lipacidogenic enzyme acetyl-CoA-carborxylase (ACC), which is activated by dephosphorylation of Ser 79 , most likely is not responsible for this enhanced lipid accumulation. PGE 2 did not affect its insulin-dependent dephosphorylation and only slightly but not significantly reduced phosphorylation by itself (see Supplementary Figure S3 ). Similarly, PGE 2 did not modulate the phosphorylation and activation of AMPdependent kinase, an upstream regulator of ACC (not shown). Therefore, additional potential mechanisms were examined.
PGE 2 -Dependent Inhibition of Lipolysis and Mitochondrial b-Oxidation
Lipid accumulation in hepatocytes represents an equilibrium between de novo synthesis on one side balanced by lipolysis and b-oxidation or secretion in the form of VLDL on the other. In the liver, the rate-controlling step in triglyceride breakdown is catalyzed by adipose triglyceride lipase (ATGL). 25, 26 As previously shown for adipocytes, 27 insulin decreased ATGL expression in hepatocytes both at low (10 mM) or high (25 mM) glucose concentration (Figure 4a) . Unexpectedly, PGE 2 also decreased ATGL expression. At lowglucose concentrations, the PGE 2 -dependent repression was additive to the insulin-dependent repression. Fatty acids released from intrahepatic triglycerides may enter b-oxidation in the hepatocyte. The key regulatory step in mitochondrial b-oxidation is the initiation of the transport of activated fatty acids into the mitochondrium via the carnitinpalmitoyltransferase 1 (CPT-1). In addition to allosteric regulation, CPT-1 activity is regulated on the transcriptional level. In accordance with previous studies, insulin decreased CPT-1 expression about five-fold (Figure 4a ). Unexpectedly, PGE 2 repressed CPT-1 to a similar extent as insulin, both a 10 mM and at 25 mM glucose. The PGE 2-dependent repression of CPT-1 expression was further enhanced by insulin.
The PGE 2 -dependent repression of CPT-1 resulted in an inhibition of mitochondrial b-oxidation by PGE 2 . As a consequence acetoacetate formation, which amounted to Hepatic steatosis by PGE 2 J Henkel et al 0.80 ± 0.37 nmol/g/h in control mitochondria, was reduced by 60 ± 9% and 53 ± 7% in mitochondria of insulin-or PGE 2 -treated cells, but no additivity was observed.
Inhibition of VLDL Production by Insulin and PGE 2
Lipids are also released from the hepatocyte pool via secretion of VLDL containing apolipoprotein B (ApoB), which is cotranslationally and posttranslationally loaded with lipids. MTP (microsomal transfer protein) is crucial for this lipidation of ApoB. Insulin decreased both ApoB and MTP expression by about 50% to 60% at 10 mM glucose, respectively. PGE 2 decreased the expression to a similar extent as insulin (Figure 4b ). Most notably, the PGE 2 -dependent repression was further enhanced by insulin, indicating that the repression of MTP and ApoB by insulin and PGE 2 was additive. A similar pattern was observed in media containing 25 mM glucose.
Mechanism of the PGE 2 -Dependent Repression of MTP and ApoB
FoxO1 phosphorylation is supposed to cause the insulindependent repression of MTP and ApoB. Insulin induced the phosphorylation of FoxO1 about four-fold (see Supplementary Figure S4 ). PGE 2 slightly enhanced FoxO1 phosphorylation but did not affect insulin-dependent FoxO1 phosphorylation making FoxO1 phosphorylation unlikely to account for the PGE 2 -dependent repression of MTP and ApoB. Another key regulator of MTP and ApoB and CPT-1 transcription is the PPARg-coactivator-1a (PGC1a). PGE 2 reduced the PGC1a mRNA and protein level in hepatocytes cultured in presence of 10 mM glucose by more than 50% (Figure 4c and d) . Similarly, treatment of hepatocytes with insulin reduced the PGC1a mRNA and protein level by about 80%. Notably, the insulin-dependent and PGE 2 -dependent decrease in PGC1a were additive, combined treatment of hepatocytes with insulin and PGE 2 reduced the mRNA expression to about 8% of the control level. Similar results were obtained with hepatocytes cultured at higher glucose concentrations. Glucose itself did not affect PGC1a expression. The functional relevance of the PGC1a repression by PGE 2 and insulin is further corroborated by the synergistic repression of another PGC1a target gene, the gluconeogenic key regulatory enzyme phosphoenolpyruvat carboxykinase (PCK, see Supplementary Figure S5 ). To provide further Hepatic steatosis by PGE 2 J Henkel et al support of the hypothesis, the impact of forced overexpression of PGC1a in hepatocytes on the PGE 2 -dependent lipid accumulation was tested. As transfection efficiency is very low in cultures of primary hepatocytes no changes in bulk lipid balance or gene expression can be expected. However, co-transfection with two plasmids encoding different fluorescent proteins showed that hepatocytes incorporated either both or none of the plasmids upon co-transfection (not shown). Hence, to allow identification of transfected cells, a plasmid encoding CFP was co-transfected together with either an empty mock vector or an expression vector for PGC1a. Lipid accumulation was determined by staining with the fluorescent dye BODIPY ( Figure 5 ). PGE 2 enhanced lipid accumulation in non-transfected and mocktransfected hepatocytes. By contrast, the PGE 2 -dependent lipid accumulation was completely blunted in cells overexpressing PGC1a. Similarly, the PGE 2 -dependent decrease in expression of a reporter gene under the control of the PCK promoter was abolished by forced expression of PGC1a (Supplementary Figure S6) .
DISCUSSION
In patients suffering from the metabolic syndrome, the exceedingly elevated plasma insulin concentration has been implicated in the development of hepatic steatosis by stimulating de novo lipogenesis and by inhibiting fatty acid oxidation and triglyceride export. A recent study 8 showed that PGE 2 , which is produced in non-parenchymal liver cells, attenuated insulin signaling in hepatocytes (Figure 2 ) by a sustained activation of ERK1/2 (Supplementary Figure S1) . 8 PGE 2 might thus alleviate the impact of insulin on the development of steatosis. In accordance with such a hypothesis, PGE 2 attenuated the insulin-dependent induction of SREBP-1c ( Figure 2 ) and its target genes FAS ( Figure 2 ) and glucokinase (Supplementary Figure S2) . At variance with expectations PGE 2 nevertheless increased the net incorporation of glucose into hepatic triglycerides ( Figure 3 ) most likely by a repression of ATGL-mediated lipolysis (Figure 4a ), mitochondrial b-oxidation (Figure 4a ) and VLDL synthesis (Figure 4b) . A possible common underlying mechanism is the repression of PGC1a by PGE 2 (Figures 4c, d and 5) . As a consequence, PGE 2 might exacerbate hepatocyte steatosis in the course of the metabolic syndrome rather than preventing it.
In Vivo support for a Role of Prostaglandin E 2 in the Development of NAFLD and NASH The relevance of the current finding is supported by a number of in vivo studies. Local production of PGE 2 in the liver depends on phospholipase A2, which liberates arachidonic acid from phospholipids, cyclooxygenases to generate PGH 2 , and PGE synthases, which isomerize PGH 2 to PGE 2 . 6,23 Inducible COX2 and mPGES1, which are expressed after induction by proinflammatory stimuli, and mPGES2, which is induced in livers of LPS-treated mice and patients with hepatitis C infection, 5, 23 are responsible for inflammationelicited PGE 2 biosynthesis that is blunted in mPGES1 À / À mice. 28, 29 COX2, mPGES1 and mPGES2 were induced in livers of diet-induced and genetic obesity mouse models (Figure 1, Supplementary Table S1 ). Similarly, COX2 was induced in livers of mice with methionine-choline-deficient diet-induced steatosis. 30, 31 In these NASH models, inflammatory cells recruited into the liver might contribute to prostaglandin E 2 in addition to resident macrophages. Inhibition of prostanoid synthesis in a NASH mouse model with a selective COX2 inhibitor not only attenuated the liver damage and signs of inflammation but, most notably, also improved steatosis. 32 Surprisingly, this study detected COX2 immune reactivity not only in resident and infiltrating immune cells but also in hepatocytes, which normally express neither COX1 nor COX2 or mPGES1 and do not produce PGE 2 . Although COX2-expression was not affected, mPGES1 was induced in cytokine-treated hepatocytes (Henkel et al., unpublished data). If indeed the hepatocyte compartment additionally produces prostaglandins in the course of NASH development, the prostaglandin burden might actually be much higher than that would be expected if nonparenchymal cells and infiltrating mononuclear cells were the only source. In further support for a potential impact of eicosanoids on the development of steatosis, high-fat diet induced intrahepatic fat accumulation and signs of liver damage in high-fat diet-induced NAFLD was reduced by knockdown of the group IVA phospholipase A2, which furnishes arachidonic acid as substrate for COX2-dependent prostaglandin formation. These changes were paralleled by a pronounced decrease of the plasma PGE 2 concentration in these mice. 33, 34 Possible Mechanism Underlying PGE 2 -Dependent Triglyceride Accumulation in Hepatocytes One important pathway by which triglyceride accumulation in hepatocytes is entailed is de novo lipogenesis. In contrast to rodents on normal chow, lipogenesis is neglible in healthy humans but increases in the course of NAFLD development as a result of persistently elevated insulin and glucose plasma concentrations, which result in the induction of key liponeogenic enzymes via SREBP and ChREBP activation, respectively. 2 The increase in de novo lipogenesis actually precedes the development of steatosis. PGE 2 in the current study slightly reduced the mRNA levels of SREBP-1c and FAS and attenuated their insulin-dependent induction. Therefore, a PGE 2 -dependent stimulation of de novo lipogenesis can be excluded as the reason for the enhanced incorporation of glucose in to triglycerides. Rather, glucose probably furnished the activated glycerol for the glycerol backbone of triglycerides. The triglyceride accumulation would then be a result of redirecting fatty acids from combustion to esterification and the redistribution for triglycerides between secreted lipoproteins and intracellular stores. The PGE 2 -dependent repression of ATGL (Figure 4a ), CPT-1 (Figure 4a ), the inhibition of ketogenesis and the repression of ApoB and MTP (Figure 4b ) support this view. Overexpression of ATGL has previously been shown to counteract hepatic steatosis in obese mice. 35 The central role of CPT-1 in the development of hepatic steatosis has also been shown both in vivo and in vitro: moderate overexpression 36 or induction of CPT-1 has been shown to improve diet-induced steatosis of the liver in different NASH models. 37, 38 By contrast, a reduction of CPT-1 activity along with other mitochondrial defects, which preceded the development of steatosis and NASH, has been implicated as leading cause for disease development in the Otsuka Long-Evans Tokushima Fatty rat model of NASH. 39 In further support of a contribution of impaired mitochondrial b-oxidation to steatosis, inhibition of CPT-1 has been identified as a possible underlying mechanism in drug-induced steatosis. 40 Development of steatosis was also favored by other defects of mitochondrial b-oxidation such as heterozygous deletion of mitochondrial trifunctional protein or knockdown of long chain acyl-CoA dehydrogenase. 41, 42 Similarly, impairment of VLDL synthesis has been implicated as a possible contributor to fat accumulation in hepatocytes in a polygenic mouse model of NASH. 43 As in the current study, lipid accumulation occurred in this mouse model despite reduction of SREBP-1c and FAS expression. Although a defect of hepatic mitochondrial b-oxidation reflected by a repression of CPT-1 might also be relevant in this model, a reduction of VLDL production due to low MTP levels was identified as the major cause. Steatosis and insulin resistance in this mouse model of NASH were largely improved by overexpression of MTP, which resulted in a rescue of VLDL production. 43 Notably, rescue of MTP expression not only improved steatosis in this model but also reduced signs of inflammation. In further support of the relevance of MTP in the development of steatosis, inhibition of MTP has been shown to contribute to drug-or alcoholinduced hepatic steatosis. 44, 45 Although development of steatosis, hepatic insulin resistance and NASH are closely correlated, the evidence for a causal interrelation is controversial. Efficient storage of fatty acids in triglycerides may actually protect the liver from adverse effects caused by high concentrations of circulating non-esterified fatty acids. 46, 47 This could explain why in some in vivo experiments PGE 2 had beneficial effects on the development of NASH, 48, 49 whereas others 32-34 (see above) rather support the view that PGE 2 has a negative impact on the development of steatosis.
The current study showed that PGE 2 increased triglyceride accumulation in hepatocytes most likely by a combined inhibition of b-oxidation due to CPT-1 repression and a reduced VLDL production due to repression of ApoB and MTP, all of which are downstream targets of PGC1a. PGC1a, which is known to be induced by an increase in cellular cAMP, 50 was also repressed by PGE 2 , most likely by activation of the Gi-coupled EP3 receptor, which has previously been shown be responsible for the PGE 2 -dependent repression of PCK in hepatocytes. 51 The hypothesis that the repression of PGC1a might be the underlying mechanism of the
